Replies to post #128272 on Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

how the hell does Gerald get 33-Mil free shares?

https://backend.otcmarkets.com/otcapi/company/financial-report/193924/content

and his faithful loyal shareholders who have been fleeced out of everything they invested on a massive 1-100 RS predicated on floorless toxic convertibles have had to average down, and average down, and average down again?

On May 10, 2018, the Board of Directors approved a conversion into common shares of $1,284,497 in convertible securities (992830 shares of Series E Convertible Preferred Stock and 291.667 shares of Series H Convertible Preferred Stock) that its CEO, Mr. Gerald Commissiong, acquired from Infusion 51a on May 1, 2018 (the “Redemption Conversion”). The Redemption Conversion was approved at the per share price of $0.038, (the closing price on May 1, 2018), for a total of issuance of 33,802,552 common shares of Amarantus to Mr. Commissiong. Mr. Commissiong acquired Infusion 51a’s entire position (992830 shares of Series E Convertible Preferred Stock and 291.667 shares of Series H Convertible Preferred Stock) as a result of a redemption request made on February 23, 2018 by Mr. Commissiong to Infusion 51a. Prior to the redemption request, Mr. Commissiong was previously a noncontrol, non-affiliate limited partner in Infusion 51a. Mr. Commissiong made the redemption request to Infusion 51a to facilitate the completion of the Tender Exchange due to challenges Infusion 51a would have faced in participating in the Tender Exchange’s Special Purpose Vehicle that is being established to liquidate shares issuable under the Tender Exchange. At the time of the redemption request, at the time of the completion of the redemption request, and throughout the term of his limited partnership in Infusion 51a, Mr. Commissiong was not an affiliate of Infusion 51a, and in no way exercised control or influence over Infusion 51a’s decisions regarding its investment in Amarantus, or any other entity. Mr. Commissiong became a passive limited partner of Infusion 51a as a result of the contribution of his ownership position in Vivacitas Oncology, Inc. (that he obtained as a co-founder of Vivacitas Oncology with Dr. Joseph Rubinfeld) to Infusion 51a in Q4/2016 at the request of Vivacitas Oncology’s then Chief Executive Officer Dr. Joseph Rubinfeld. At the time of Mr. Commissiong’s redemption request, and at the time of its completion, Amarantus Bioscience Holdings, Inc. investments held by Infusion 51a represented less than 10% of Infusion 51a’s assets under management.

...if anything, Gerald should be giving those shares back to his beleaguered and decimated shareholders, instead of putting them in his pocket...what a cold hearted bastard!

SMH